Everett E. Vokes to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Everett E. Vokes has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.858
-
Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
Score: 0.427
-
Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol. 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2.
Score: 0.070
-
Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01; 23(25):5853-5.
Score: 0.064
-
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5045s-5050s.
Score: 0.063
-
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003; 8(4):350-60.
Score: 0.053
-
Searching for a standard. J Clin Oncol. 2002 Jan 15; 20(2):359-61.
Score: 0.050
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
Score: 0.047
-
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892.
Score: 0.036
-
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106.
Score: 0.032
-
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006 Jan 20; 24(3):407-12.
Score: 0.016